|Bid||0.22 x 12352300|
|Ask||0.23 x 3288900|
|Day's Range||0.22 - 0.23|
|52 Week Range||0.11 - 0.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 30, 2016 - Sep 3, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
NASDAQ: BNTCW) today announced that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to BB-301 for the treatment of oculopharyngeal muscular dystrophy (OPMD). The Orphan Drug Designation granted to Benitec may provide a range of valuable benefits, including fast track process for clinical regulatory approval, potential extension of patent life with a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees. In short, a clear and expeditious path for cost-efficient development and commercialisation.
Categories: Yahoo FinanceGet free summary analysis Benitec Biopharma Ltd. reports financial results for the half-year ended June 30, 2017. Highlights Summary numbers: Revenues of AUD 0.16 million, Net Earnings of AUD -2.73 million. Gross margins widened from -5,423.73% to -1,568.52% compared to the same period last year, operating (EBITDA) margins now -4,484.57% from -16,830.51%. Earnings growth from ... Read more (Read more...)
Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.
NASDAQ:BNTCW) is pleased to announce it has submitted an application with the U.S. Food & Drug Administration (FDA) seeking orphan drug designation for BB-301 as a treatment of oculopharyngeal muscular dystrophy (OPMD). BB-301 is a single vector (gene therapy construct) system which uses DNA directed RNA interference (ddRNAi) to silence expression of the mutant gene associated with OPMD, while simultaneously adding back a copy of the normal version of the same gene to restore gene function. To receive orphan drug designation from the FDA, a company must demonstrate that the condition addressed by the drug or biologic affects less than 200,000 persons in the U.S. The company must also provide the FDA with sufficient information to establish a medically plausible basis for expecting the product will be an effective treatment.
SYDNEY/MELBOURNE, Oct 31 (Reuters) - Battery makers are increasingly turning to nickel to help power growing global electric car sales, but only half of the world's producers of the metal are likely to benefit, mining analysts and executives say. Lithium batteries containing nickel, which helps keep a charge over longer distances, are being installed in electric cars from Tesla's top-of-the-line Model X to General Motors Co modestly-priced Chevy Bolt. The battery boom promises a new and growing market for miners producing high-grade nickel products.
SYDNEY , Oct. 18, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that a new patent relating to the Company's hepatitis B program has been issued ...
NASDAQ: BNTCW) is pleased to announce it has developed a new single vector (gene therapy construct) system which uses DNA directed RNA interference (ddRNAi) to silence expression of the mutant gene associated with oculopharyngeal muscular dystrophy (OPMD), while simultaneously adding back a copy of the normal version of the same gene to restore gene function. This next generation single vector system, termed BB-301, represents the clinical candidate that Benitec intends to advance into human clinical trials in the second half of calendar year 2018.
Paratek, Cyclacel and Benitec stocks led a biotech surge on Tuesday, rising on strong trial results.
NASDAQ: BNTCW) is pleased to announce that the initial pre-clinical efficacy results of the OPMD program have been published in Nature Communications, an open access scientific journal published by the Nature Publishing Group. OPMD, a rare progressive muscle-wasting disease caused by mutation in the poly(A)-binding protein nuclear 1 (PABPN1) gene, is characterised by eyelid drooping, swallowing difficulties, and proximal limb weakness.
SYDNEY, March 13, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) (Benitec) today announced that in accordance with the Share Subscription Agreement dated 24 October ...
SYDNEY, Feb. 16, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that it will present pivotal data from the Company's hepatitis B virus (HBV) in vivo ...
Benitec Biopharma saw its shares more than double on Tuesday after the company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases.
The results of this work will be presented by Dr David Suhy, Benitec's Chief Scientific Officer, at the Association for Research in Vision and Ophthalmology (ARVO)-Asia meeting being held in Brisbane on February 5th to February 8th, and the Translational Vision Summit (TVS), being held in conjunction. ARVO-Asia is a leading conference dedicated to eye and vision research in the Asia-Pacific region.
NASDAQ: BNTCW) is pleased to announce that it has initiated work on two new oncology pipeline programs after executing a Research Collaboration Agreement with Nant Capital LLC (Nant). This transaction represents a further step in establishing a strategic alliance with Nant around the development and funding of the head and neck cancer squamous cell carcinoma (HNSCC) programs. Greg West, CEO said, "We have hit the ground running in launching into the development of these two oncology programs.